High affinity humanized monoclonal antibodies to complement products including C5, C5a and C5aR to block the activities of the anaphylatoxin and the formation of membrane attack complex (MAC) associated with ARDS in COVID-19 have been developed for reducing hypoxia and increasing survival in patients with severe COVID-19 [47,50]. This evidence concerns the gene C5AR1 and COVID-19.